

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  C07C 317/32, 233/22, 315/04, C07D 301/19, 263/14, A61K 31/16		A1	(11) International Publication Number: WO 94/14764  (43) International Publication Date: 7 July 1994 (07.07.94)
<p>(21) International Application Number: PCT/US93/12071</p> <p>(22) International Filing Date: 15 December 1993 (15.12.93)</p> <p>(30) Priority Data: 07/993,932 18 December 1992 (18.12.92) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 07/993,932 (CIP) Filed on 18 December 1992 (18.12.92)</p> <p>(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenvilworth, NJ 07033 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): WU, Guang-Zhong [CN/US]; 7 Cottage Place, Somerville, NJ 08876 (US). TORMOS, Wanda, L [US/US]; Apartment 9P, 330 West Jersey Street, Elizabeth, NJ 07202 (US).</p> <p>(74) Agents: THOMPSON, Paul, A. et al.; Schering-Plough Corporation, One Giralda Farms, M3W, Madison, NJ 07940-1000 (US).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ASYMMETRIC PROCESS FOR PREPARING FLORFENICOL, THIAMPHENICOL, CHLORAMPHENICOL AND OXA-ZOLINE INTERMEDIATES</p> <p>(57) Abstract</p> <p>The present invention comprises a process for the asymmetric synthesis of florfenicol, thiamphenicol or chloramphenicol. In an alternative embodiment, the present invention comprises a process for isomerizing of the S,S-isomer of florfenicol to the R,S-isomer (I) by sequentially treating with: (i) a lower alkylsulfonyl chloride and a tertiary amine base; (ii) sulfuric acid and water; (iii) an alkali metal hydroxide. The present invention further comprises a process for regioselectively opening an epoxide to form a <i>threo</i>-oxazoline.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


**ASYMMETRIC PROCESS FOR PREPARING FLORFENICOL,  
THIAMPHENICOL, CHLORAMPHENICOL AND OXAZOLINE  
INTERMEDIATES**

5           The present invention relates to a stereospecific process for preparing florfenicol, thiamphenicol and chloramphenicol having the correct relative and absolute stereochemistry from achiral starting materials. The present invention also relates to a process for isomerizing the S,S-enantiomer of florfenicol to florfenicol having the 10 proper R,S stereochemistry. In addition, the present invention relates to a stereospecific process for preparing oxazoline intermediates useful in the synthesis of florfenicol, thiamphenicol, chloramphenicol, and related antibiotics.

15           **BACKGROUND OF THE INVENTION**

Florfenicol (I) is a broad spectrum antibiotic having activity against Gram positive, Gram negative and thiamphenicol-resistant bacteria, as disclosed in U.S. Patent No. 4,235,892.


20



Thiamphenicol (IX) and chloramphenicol (X) are structurally related antibiotics known in the art.


25

- 2 -




5 Several approaches to the synthesis of florfenicol have  
been reported, e.g. Tyson, Chem Ind., (1988) pp. 118-122; and U.S.  
4,743,700. However, these processes typically suffer from low overall  
yields and require either a resolution step or expensive chiral starting  
materials.

10 Schumacher et al., *J. Org. Chem.*, **55**, 18 (1990) pp. 5291-  
5294, describes a synthesis of florfenicol starting from a commercially  
available chiral starting material, e.g. compound (1). Compound (1) is  
converted to the oxazoline (2), to protect the secondary hydroxyl group,  
and (2) is converted to the fluoride (3). The oxazoline protecting group  
15 is removed by treatment with acid and the resulting amino-alcohol (4)  
converted to florfenicol I. However, the Schumacher et al. process  
again requires the use of expensive chiral starting materials.




- 3 -



Clark et al., in *Synthesis*, (1991) pp. 891-894, disclose a process for the synthesis of florfenicol via the stereoselective hydrolysis of ethyl D,L-*threo*-3-(4-methylthiophenyl)-serinate hydrochloride (5) using enzymes to give (2S,3R)-3-(4-methylthiophenyl)serine (7) and the unreacted ester ethyl (2R,3S)-3-(4-methylthiophenyl)serinate hydrochloride (6). The acid (7), and the ester (6), are then converted via alternative multi-step sequences to the R,R-oxazoline (2). Compound (2) is then converted to florfenicol by the process of Schumacher et al., described above.

- 4 -



5 The Clark et al. process, while avoiding the use of expensive chiral starting materials, is chemically inefficient, producing a mixture of chiral ester (6) and acid (7) which must be separately converted to (2). Thus, the prior art does not teach a chemically efficient stereoselective process for the synthesis of florfenicol that avoids the use of expensive chiral precursors.


- 5 -

**SUMMARY OF THE INVENTION**


The present invention comprises a process for the asymmetric synthesis of florfenicol, thiamphenicol or chloramphenicol

5 comprising the steps:

(c) regioselectively opening a chiral epoxide of the formula




10 wherein R is nitro or methanesulfonyl, by sequentially treating with a strong base, a Lewis acid and dichloroacetonitrile to form an oxazoline of the formula



15 wherein R is as defined above;

(d) stereoselective inversion/isomerization of the oxazoline of step (c) by sequentially treating with: (i) a lower alkylsulfonyl chloride and a tertiary amine base; (ii) aqueous acid; and (iii) an alkali metal hydroxide; to form an oxazoline of the formula

20



wherein R is as defined above; and

- 6 -

(e) either:


5 (i) wherein R is methanesulfonyl, treating the oxazoline of step (d) with a fluorinating agent, then hydrolyzing the oxazoline with acid to obtain florfenicol; or

(ii) hydrolyzing the oxazoline of step (d) with acid to obtain:

(a) wherein R is methanesulfonyl, thiamphenicol; or

(b) wherein R is nitro, chloramphenicol.

10 Preferably the chiral epoxide of step (c) is prepared from a trans cinnamic acid derivative of the formula




wherein R is nitro or methanesulfonyl, by:

15 (a) converting the acid to an acid chloride using a chlorinating agent, and reducing the acid chloride to a trans allylic alcohol with a reducing agent;

(b) asymmetrically epoxidizing the allylic alcohol of step (a), by reacting with t-butylhydroperoxide in the presence of a chiral

20 epoxidation catalyst prepared from titanium (IV) isopropoxide and L-diisopropyltartaric acid, to form the chiral epoxide of the formula



25 wherein R is as defined above.

Preferred is a process as described above wherein the chlorinating agent of step (a) is thionyl chloride, the reducing agent of step (a) is NaBH4, the lower alkylsulfonyl chloride of step (d) is MsCl, the tertiary amine base of step (d) is triethylamine, the aqueous acid of step


- 7 -

(d) is sulfuric acid, the alkali metal hydroxide of step (d) is NaOH, the fluorinating agent of step (e) is  $\text{CF}_3\text{CH}(\text{F})\text{CF}_2\text{N}(\text{C}_2\text{H}_5)_2$ , and the acid of step (e) is AcOH.

More preferred is a process as described above wherein  
 5 the strong base of step (c) is an alkali metal hydride, preferably sodium hydride, and the Lewis acid of step (c) is zinc chloride.


In an alternative embodiment, the process of the instant invention comprises the isomerization of the S,S-isomer of florfenicol to the R,S-isomer (I) by sequentially treating with: (i) a lower alkylsulfonyl  
 10 chloride and a tertiary amine base; (ii) aqueous acid; (iii) an alkali metal hydroxide.

In a third embodiment the process of present invention comprises a process for regioselectively opening an epoxide of the formula



wherein  $\text{R}^1$  is methanesulfonyl, nitro or hydrogen by sequentially treating with a strong base, a Lewis acid and dichloroacetonitrile to form a *threo*-oxazoline of the formula

20



respectively, wherein  $\text{R}^1$  is as defined above. The epoxide opening process can be carried out on chiral (as shown) or racemic starting

25 materials. Where chiral starting materials are used the reaction is both regio- and stereo-selective, producing chiral oxazolines.

- 8 -

Preferred is a process for preparing an oxazoline as described above wherein the strong base is an alkali metal hydride, preferably sodium hydride, and the Lewis acid is zinc chloride.

The process of the present invention does not suffer the 5 shortcomings of the prior art processes. It is chemically efficient, proceeds in high yield, and avoids the problems of expensive chiral starting materials by utilizing a reusable chiral auxiliary to introduce optical activity.

## 10 DETAILED DESCRIPTION

As used herein:

"fluorinating agent" is a reagent or combination of reagents capable of converting a primary alcohol to the analogous fluoride.

15 Preferred fluorinating agents include:  $\alpha,\alpha$ -difluoroalkylamine fluorinating agents disclosed in U.S. Patent No. 4,876,352, such as N-(1,1,2,3,3,3-hexafluoropropyl)diethylamine; HF; phosphorous fluorides; 2-chloro-1,1,2-trifluorotriethylamine; and inorganic fluoride, such as LiF, in a polyol solvent. Most preferred is N-(1,1,2,3,3,3-hexafluoropropyl)-20 diethylamine.

"lower alkyl" means a saturated hydrocarbon chain having from 1-6 carbon atoms, the chain being straight or branched;

"alkali metal hydroxide" means sodium, lithium or potassium hydroxide, preferably NaOH;

25 "strong base" means a strong nonaqueous base selected from the group consisting of alkali metal hydride, alkali metal alkoxide and lower alkyl lithium;

"alkali metal hydride" means sodium, lithium or potassium hydride, preferably sodium hydride;

30 "alkali metal alkoxide" means an alkali metal salt of a lower alkyl alcohol. Preferred alkali metal alkoxides are alkali metal methoxides, ethoxides, iso-propoxides and tert-butoxides. Most preferred are potassium t-butoxide, potassium methoxide, sodium methoxide and sodium ethoxide.

- 9 -

"lower alkylolithium" is an alkylolithium selected from n-butyllithium, sec-butyllithium and tert-butyllithium;

"aqueous acid" means a solution of a protic acid selected inorganic acids, such as  $H_2SO_4$  or  $HCl$ , and organic acids, such as

5  $AcOH$ , in water;

"Lewis acid" means an inorganic salt selected from the group consisting of zinc chloride, magnesium chloride and manganese chloride;

10 "chlorinating agent" is a reagent capable of converting a carboxylic acid to the analogous acid chloride, such as  $SOCl_2$  or oxaly chloride, and is preferably  $SOCl_2$ ; and

"reducing agent" is a reagent which can convert a conjugated acid chloride to an allylic alcohol, such as  $NaBH_4$  or sodium cyanoborohydride, and is preferably  $NaBH_4$ .


15 As used herein the following reagents are identified by the indicated abbreviations: dimethylsulfide (DMS); diisopropyl L-tartaric acid (L-DIPT); tetrahydrofuran (THF); ethyl acetate (EtOAc); methyl isobutylketone (MIBK); methanesulfonyl chloride (MsCl); ethanol (EtOH); acetic acid (AcOH).

20 In one aspect, designated Method A, the process of the present invention involves the conversion of a para-R-substituted derivative of E-cinnamic acid, wherein the substituent R is nitro or methanesulfonyl, to florfenicol, thiamphenicol or chloramphenicol according to Reaction Scheme A. The process is stereospecific,

25 producing florfenicol, thiamphenicol or chloramphenicol having the requisite absolute stereochemistry, e.g. R,S for florfenicol, and R,R for thiamphenicol and chloramphenicol.


Reaction Scheme A:

30 Step A1




- 10 -


## Step A2




## Step A3




## Step A4



## 10 Step A5(i)




## Step A5(iiA)



- 11 -

## Step A5(iiib)



In Method A, step A1, the E-cinnamic acid derivative II is

5 reacted with a chlorinating agent, such as  $\text{SOCl}_2$ , in the presence of a suitable solvent, e.g.  $\text{CH}_2\text{Cl}_2$ , at reflux temperature for a period of 30 to 90 min., preferably about 1 h., to form the analogous acid chloride. The acid chloride is treated with a reducing agent, such as  $\text{NaBH}_4$ , in an alcohol solvent, e.g.  $\text{EtOH}$ , at -10 to +25°C, preferably at -5 to +10 °C, for

10 a period of 30 to 90 min., preferably about 1 h., followed by quenching in a mixture of ice/water and a suitable acid, such as  $\text{HCl}$ , and isolating the product E-allylic alcohol III by extracting with  $\text{CH}_2\text{Cl}_2$ .

In step A2, the E-allylic alcohol (III) of step A1 is epoxidized using the so-called "Sharpless epoxidation", as described

15 by Sharpless, et al. in *J. Amer. Chem. Soc.*, 102, (1980) 5974. The Sharpless catalyst is prepared by combining equimolar amounts of L-DIPT and titanium (IV) isopropoxide in the presence of 4 Å molecular sieves, and stirring at about -20°C for about 1/2 h. The allylic alcohol of step A1, as a solution in  $\text{CH}_2\text{Cl}_2$ , and a 3 M solution of t-butyl-

20 hydroperoxide in 2,2,4-trimethylpentane are slowly added, preferably in a dropwise manner, to the catalyst mixture at about -20°C and reacted for 2 to 6 h., preferably about 4 h. The mixture is quenched by adding DMS, followed by filtration, treatment of the filtrate with a saturated solution of  $\text{NaF}$  in water at room temperature for about 16 h., a second

25 filtration employing a filter aid, such as Celite®, and extraction of the filtrate with  $\text{CH}_2\text{Cl}_2$  to isolate the R,R-isomer (IV) of the epoxide product, having high optical purity.

Alternatively, the chiral epoxide IV can be prepared via methods well known to those skilled in the art.

- 12 -

In step A3, the epoxide IV of step A2, as a solution in a suitable solvent, such as THF, is slowly added, preferably in a dropwise manner, to a suspension of NaH in THF at -10° to 20°C, preferably at 0°C to 10°C, and most preferably at about 5°C, and reacted for about

5 1/2 h. A solution of anhydrous ZnCl<sub>2</sub> in THF is added to the cold mixture thus obtained. After about 1/2 h. at -10° to 20°C, preferably at 0° to 10°C, and most preferably about 5°C, a solution of dichloroacetonitrile in THF is added, along with 4Å molecular sieves, and the mixture stirred for about 15 min., then heated to 30° to 80°C, preferably to 50° to 60°C, 10 and most preferably about 55°C, for about 16 h. The resulting mixture is cooled to room temperature, quenched by adding an aqueous solution of NaHCO<sub>3</sub>, and extracted with a suitable solvent, such as EtOAc to give the crude product, which is slurried in isopropanol, followed by filtration and drying to isolate the chiral oxazoline V.

15 In step A4, the oxazoline V of step A3 is combined with a trialkylamine, preferably triethylamine, and pyridine at room temperature. The mixture is cooled to -20° to 20°C, preferably to 0° to 10°C, and most preferably about 5°C, and an alkylsulfonyl chloride, preferably MsCl, is slowly added (preferably in a dropwise manner) to 20 the mixture, which is stirred for about 2 hours. The pH of the mixture is adjusted to 1.9 to 4.0, preferably about 2.0, by addition of an aqueous acid, preferably H<sub>2</sub>SO<sub>4</sub>, and most preferably about 3.0 N H<sub>2</sub>SO<sub>4</sub>. THF is added to generate a homogeneous mixture. After warming to room temperature for 10 min., the mixture is treated with an alkali metal 25 hydroxide, preferably NaOH, and most preferably administered as 50% NaOH (aqueous), to bring the pH to >9.5, preferably about 12.5. Concentration of the mixture, and extraction with a suitable solvent, such as EtOAc, gave the isomerized oxazoline product VI.

In step A5(i), for preparing florfenicol, the isomerized 30 oxazoline VI, wherein R is methanesulfonyl, of step A4 is fluorinated via the process disclosed in U.S. Patent No. 4,876,352, then hydrolyzed by treating with acid. The fluorination is preferably carried out by treating the oxazoline VI with N-(1,1,1,2,3,3-hexafluoropropyl)-diethylamine in a suitable solvent, e.g. CH<sub>2</sub>Cl<sub>2</sub>, in a bomb at a temperature of about 35 110°C. The hydrolysis of the resulting fluoro-oxazoline intermediate is

- 13 -


preferably carried out by addition of 1 N H<sub>2</sub>SO<sub>4</sub>, aqueous, to adjust the pH to 6.5-6.0, then by addition of AcOH to further acidify the mixture to a pH of about 5.5-5.0.

In steps A5(iia) and A5(iib), for preparing thiamphenicol or 5 chloramphenicol, respectively, the isomerized oxazoline VI of step A4 is hydrolyzed by treating with acid to produce: (a) wherein R is methanesulfonyl, thiamphenicol; or (b) wherein R is nitro, chloramphenicol. The hydrolysis of the oxazoline is preferably carried out by addition of 1 N H<sub>2</sub>SO<sub>4</sub>, aqueous, to adjust the pH to 6.5-6.0, then 10 by addition of AcOH to further acidify the mixture to a pH of about 5.5-5.0.

Starting compounds of formula II can be prepared via methods well known to those skilled in the art, e.g. the procedure of Preparation 1 (described below).

15 In another alternative aspect, Method B, the present invention is a process, as outlined in Reaction Scheme B, for converting the S,S-isomer of florfenicol (VII), [which is readily prepared via known methods from intermediates disclosed by Clark et al., in Synthesis, (1991) pp. 891-894], to the correct R,S-isomer I. The isomerization is 20 stereospecific and proceeds via an oxazoline intermediate VIII, which is not isolated but converted directly to florfenicol I.

- 14 -

Reaction Scheme B:

5        The isomerization of Method B is carried out using a procedure similar to that described in Method A, step A4. The S,S-isomer of florfenicol is combined with a trialkylamine, preferably triethylamine, and pyridine at room temperature. The mixture is cooled to -20° to 20°C, preferably to 0° to 10°C, and most preferably about 5°C,

10      and an alkylsulfonyl chloride, preferably MsCl, is slowly added (preferably in a dropwise manner) to the mixture, which is stirred for about 2 hours. The mixture is treated with an alkali metal hydroxide, preferably NaOH, and most preferably administered as 50% NaOH (aqueous), to bring the pH to about 12.5 to form an oxazoline


15      intermediate VIII. The oxazoline VIII is treated with an aqueous solution of an acid, such as HOAc, at room temperature to give the correct R,S-isomer of florfenicol I.

- 15 -

In a third aspect, Method C, the present invention is a process, as outlined in Reaction Scheme C, for regioselectively opening an epoxide of the formula XI, wherein R<sup>1</sup> is as defined above, to form an oxazoline of the formula XII, wherein R<sup>1</sup> is as defined above. The 5 process is regiospecific, producing oxazoline products. In contrast, the prior art teaches opening of epoxides XI to occur via attack at the benzylic carbon atom.

Reaction Scheme C:

10



15

(The stereochemistry indicated in compound XII is intended to reflect relative stereochemistry only. However, where a chiral epoxide, e.g. XIa or XIb is used, the oxazoline stereochemistry represents both 20 relative and absolute stereochemistry as shown in compounds XIIa and XIIb.)


The epoxide opening of Method C is carried out via the procedure described in Method A, step A3.

- 16 -

The following preparations and examples are illustrative of the process of the present invention:

5

Preparation 1




10

Combine 312 g (2.99 mole) of malonic acid, 596 mL of pyridine, 30 mL of piperidine and 300 g (1.49 mole) of p-methylsulfonylbenzaldehyde and heat the mixture to 95-100°C for 4 h. Cool the mixture to room temperature and slowly pour into 3 L of a mixture of HCl,

15


water and ice. Collect the resulting precipitate by filtration and dry the solid to give 340 g (83% yield) of the E-cinnamic acid derivative, m.p. = 294-296°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, ppm): 7.96 (s, 4H); 7.78 (d, J = 16 Hz, 1H); 6.71 (d, J = 16 Hz, 1H); 3.5 (br. s, 1H); 3.25 (s, 3H).

- 17 -

Example 1Step A:

5

Combine 96 mL (1.35 mole) of  $\text{SOCl}_2$  and 50 g (0.225 mole) of the product of Preparation 1 and heat the mixture at reflux for 1 hour. Distill off the excess  $\text{SOCl}_2$ , then add 100 mL of  $\text{CH}_2\text{Cl}_2$ . Add the resulting solution (dropwise) to a precooled (-5°C) mixture of 42 g (1.1 mole) of  $\text{NaBH}_4$  and 500 mL of EtOH. Stir the mixture for 1 h. at 10°C, then quench by pouring into a mixture of HCl, water and ice. Extract with  $\text{CH}_2\text{Cl}_2$  (3 X 300 mL), combine the extracts, concentrate and filter to give 28 g (74% yield) of the product allylic alcohol, m.p. = 126-127°C.  $^1\text{H NMR}$  ( $\text{CDCl}_3$ , ppm): 7.85 (d,  $J = 9$  Hz, 2H); 6.52 (d of t,  $J = 16$  Hz, 5 Hz, 1H); 4.38 (d of d,  $J = 5$  Hz, 1 Hz, 2H); 3.05 (s, 3H); 1.93 (br. s, 1H).

Step B:

20


Combine 8 g of 4Å molecular sieves, 1.74 g (7.4 mmol) of L-DIPT and 2.16 g (7.4 mmol) of titanium (IV) isopropoxide at -20°C under anhydrous conditions, and stir for 30 min. Add (dropwise) a solution of 8.1 g (37 mmol) of the allylic alcohol of step A in 500 mL of  $\text{CH}_2\text{Cl}_2$ , and 13.4 mL of a 3.0 M solution of t-butyl hydroperoxide in 2,2,4-trimethylpentane. Stir the mixture at -20°C for 4 h., then quench by adding 6.0 mL of DMS. Filter the mixture, then add 250 mL of saturated NaF (aqueous) to the filtrate and stir for 16 h. at 25°C. Filter through

- 18 -

Celite®, and extract the filtrate with  $\text{CH}_2\text{Cl}_2$  (3 X 100 mL). Combine the extracts and wash with water (2 X 100 mL), then concentrate the extracts and filter to obtain 7.15 g (82% yield) of the S,S-epoxide, having an optical purity of 97% e.e. and m.p. = 104-106°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.92  
 5 (d,  $J$  = 8 Hz, 2H); 7.49 (d,  $J$  = 8 Hz, 2H); 4.10 (d of d,  $J$  = 17 Hz, 3 Hz, 1H); 4.04 (s, 1H); 3.85 (d of d,  $J$  = 17 Hz, 3 Hz, 1H); 3.20-3.17 (m, 1H); 3.05 (s, 3H); 1.88 (br. s, 1H). The optical purity of the epoxide is determined by chiral HPLC (Chiracel® OJ 25 cm x 4.6 mm id column, 25°C, 1:1 hexane/isopropanol containing 1% acetonitrile).

10


Step C:



Combine 6.1 g (153 mmol) of NaH (60% dispersion in oil)  
 15 and 90 mL of THF and cool the resulting suspension to 5°C. Add (dropwise) a solution of 30 g (128 mmol) of the epoxide of step B in 300 mL of THF, then stir the mixture at 5°C for 30 min. Add (dropwise) 17.8 g (128 mmol) of anhydrous  $\text{ZnCl}_2$  as a solution in 250 mL of THF, and stir at 5°C for 30 min. Add (dropwise) 17.0 g (153 mmol) of  $\text{CHCl}_2\text{CN}$  as a solution in 10 mL of THF, then add 1 g of 4Å molecular sieves and continue stirring at 5°C for 15 min. Heat the mixture to 55°C, stir for 16 h., then cool to room temperature and quench with  $\text{NaHCO}_3$  (aqueous). Extract with  $\text{EtOAc}$  (4 X 400 mL), combine the extracts and concentrate to a residue. Slurry the residue in isopropanol, filter and dry the solid to obtain 16.0 g of the oxazoline. The oxazoline is recrystallized from MIBK to obtain purified oxazoline (97% purity), m.p. = 156.5-157.5°C.  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.93 (d,  $J$  = 8.4 Hz, 2H); 7.60 (d,  $J$  = 8.4 Hz, 2H); 6.26 (s, 1H); 5.14 (d,  $J$  = 4 Hz, 1H); 4.57 (d of d of d,  $J$  = 8.7 Hz, 7.9 Hz, 4.0 Hz, 1H); 4.46 (d of d,  $J$  = 9.7 Hz, 7.9 Hz, 1H); 4.28 (d of d,  $J$  = 9.7 Hz, 8.7 Hz, 1H); 3.05 (s, 3H); 2.60 (br. s, 1H).

- 19 -

Step D:




5        Combine 3.5 g (10 mmol) of the oxazoline of step C, 5 mL of pyridine and 2.8 mL of triethylamine at 25°C, cool the mixture to 5°C and add (dropwise) 0.95 mL (12 mmol) of MsCl. Stir the mixture at 5°C for 2 h., then add 3.0 N H<sub>2</sub>SO<sub>4</sub> (aqueous) to adjust the pH to 2. Add 5 mL of THF, warm the mixture to room temperature and stir for 10 min.

10      Add 50% NaOH (aqueous) to adjust the pH to 12.5. Concentrate the mixture and extract with EtOAc (3 X 40 mL). Combine the extracts and concentrate to give the product having an optical purity of >99.9%. Chromatograph the product on silica gel to give purified product, m.p. = 144-145°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 8.00 (d, J = 8.3 Hz, 2H); 7.26 (s, 1H); 7.60 (d, J = 8.3 Hz, 2H); 5.75 (d, J = 6.4 Hz, 1H); 5.18 (t, J = 5.6 Hz, 1H); 4.10-4.05 (m, 1H); 3.75-3.65 (m, 1H); 3.60-3.55 (m, 1H); 3.23 (s, 3H). The optical purity of the oxazoline is determined by chiral HPLC (Chiracel® OJ 25 cm x 4.6 mm id column, 25°C, 69:30:1 hexane/isopropanol/acetonitrile).

15      20


- 20 -

Step E:

5 The oxazoline of step D is fluorinated according to the method disclosed in U.S. Patent No. 4,876,352. The resulting fluoro oxazoline is then hydrolyzed by treating with 1 N  $H_2SO_4$ , then with HOAc, using the procedure of Example 2.

Example 2

10



15 Combine 3.0 g (8.4 mmol) of the S,S-isomer of florfenicol, 3 mL of THF, 3 mL of pyridine and 2.3 mL of triethylamine, then stir while cooling to 10-15°C. Slowly add (dropwis) a solution of 1.9 g (16.8 mmol) of MsCl in 2 mL of THF to the stirred mixture, maintaining the

- 21 -

temperature at 10-15°C. Stir the resulting mixture at 10°C for 30 min., then warm to room temperature and stir for 1 h., at which point formation of the mesylate intermediate is complete. Add 10 mL of water to the mixture, cool to 10°C, then slowly add (dropwise) a solution of 2.7 g of


- 5 50% NaOH (aqueous) diluted in 5 mL of water. Stir at 10°C for 10 min., then add an additional 0.5 g of 50% NaOH and continue stirring for 10 min. more, to complete formation of the oxazoline intermediate. Add 1.0 N H<sub>2</sub>SO<sub>4</sub> (aqueous) to the mixture to adjust the pH to 6.5-6.0, then further acidify by adding HOAc until the pH reaches 5.5-5.0, at which
- 10 point a precipitate forms. Add acetone to dissolve the precipitate and stir the mixture at room temperature for 16 h. Concentrate the mixture in vacuo to remove the THF, pyridine and acetone, then stir the resulting mixture for 30 min. at room temperature. Filter and dry the solid to give the product florfenicol, 2.5 g, having the correct relative and absolute
- 15 stereochemistry.

- 22 -


We Claim:

1. A process for the asymmetric synthesis of florfenicol, thiamphenicol or chloramphenicol comprising the steps:

5 (c) regioselectively opening a chiral epoxide of the formula




10 wherein R is nitro or methanesulfonyl, by sequentially treating with a strong base, a Lewis acid and dichloroacetonitrile to form an oxazoline of the formula



15 wherein R is as defined above;

(d) stereoselective inversion/isomerization of the oxazoline of step (c) by sequentially treating with: (i) a lower alkylsulfonyl chloride and a tertiary amine base; (ii) aqueous acid; and (iii) an alkali metal hydroxide; to form an oxazoline of the formula

20



wherein R is as defined above; and


- 24 -

4. The process of claims 2 or 3 wherein: the chlorinating agent of step (a) is thionyl chloride; the reducing agent of step (a) is NaBH<sub>4</sub>.


5. 5. The process of claims 1, 2, 3 or 4 wherein: the lower alkylsulfonyl chloride of step (d) is MsCl; the tertiary amine base of step (d) is triethylamine; the aqueous acid of step (d) is sulfuric acid; the alkali metal hydroxide of step (d) is NaOH; the fluorinating agent of step (e) is CF<sub>3</sub>CH(F)CF<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>; and the acid of step (e) is AcOH.

10 6. The process of claims 1, 2, 3, 4 or 5 wherein in step (d) sufficient aqueous acid is used to adjust the pH to 1.9 to 4.0, and sufficient alkali metal hydroxide is used to adjust the pH to > 9.5.

15 7. A process for regioselectively opening an epoxide of the formula



wherein R<sup>1</sup> is methanesulfonyl, nitro or hydrogen by sequentially 20 treating with a strong base, a Lewis acid and dichloroacetonitrile, to form an oxazoline of the formula



25 having *threo* relative stereochemistry, wherein R<sup>1</sup> is as defined above.

- 25 -

8. The process of claims 1, 2, 3, 4, 5, 6 or 7 wherein the strong base is an alkali metal hydride and the Lewis acid is zinc chloride.
- 5 9. The process of claim 8 wherein the alkali metal hydride is NaH.
10. A process for preparing florfenicol, comprising the isomerization of the S,S-isomer of florfenicol to the R,S-isomer (I) by sequentially treating with: (i) a lower alkylsulfonyl chloride and a tertiary amine base; (ii) aqueous acid; (iii) an alkali metal hydroxide.

# INTERNATIONAL SEARCH REPORT

In ntional Application No  
PCT/US 93/12071

## A. CLASSIFICATION OF SUBJECT MATTER

C 07 C 317/32, C 07 C 233/22, C 07 C 315/04,  
C 07 D 301/19, C 07 D 263/14, A 61 K 31/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C 07 C 317/00, C 07 C 315/00, C 07 C 233/00,  
C 07 D 301/00, C 07 D 263/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 92/07 824 (SCHERING) 14 May 1992 (14.05.92), claims 1-3, 7. --	1
A	EP, A2, 0 423 705 (ZAMBON) 24 April 1991 (24.04.91), claims 1-17. --	1
A	US, A, 4 876 352 (DORIS B. SCHUMACHER et al.) 24 October 1989 (24.10.89), claim 1. --	1, 5
A	US, A, 4 235 892 (TATTANAHALI L. NAGABHUSHAN) 25 November 1980 (25.11.80), abstract; column 7, line 26 -	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

21 February 1994

Date of mailing of the international search report

28.04.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentdaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

REIF e.h.

## INTERNATIONAL SEARCH REPORT

-2-

Inte	rnational Application No
	PCT/US 93/12071

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	column 9, line 23. -- EP, A1, 0 472 790 (ARCO CHEMICAL) 04 March 1992 (04.03.92), abstract. --	1-3
A	US, A, 4 900 847 (ROBERT M. HANSON et al.) 13 February 1990 (13.02.90), claims 1,3,4,6. --	1-3
A	CHEMICAL ABSTRACTS, vol. 107, no. 1, issued 1987, July 06, Columbus, Ohio, USA JOMMI, GIANCARLO et al. "2-Oxazolidinones as regio- selective protection of beta- -amino alcohols in the syn- thesis of 2-amino-1-aryl-3- -fluoro-1-propanols" page 632, column 1, abstract- -no. 107:6859m & Gazz. Chim. Ital. 1986, 116(9), 485-9. -----	1

## ANHANG

zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

## ANNEX

to the International Search Report to the International Patent Application No.

## ANNEXE

au rapport de recherche international relatif à la demande de brevet international n°

PCT/US 93/12071 SAE 83731

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unter-richtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visé ci-dessus. Les renseignements fournis sont donnés à titre indica-tif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9207824	14-05-92	AU A1 89279/91 CA AA 2094810 EP A1 555340 HU A0 9301182 JP T2 5507289	26-05-92 26-04-92 18-08-93 30-08-93 21-10-93
EP A2 423705	24-04-91	EP A3 423705 IT A0 8922075 IT A 1237798 JP A2 3188050 US A 5202484	06-05-92 20-10-89 17-06-93 16-08-91 13-04-93
US A 4876352	24-10-89	AU A1 43110/89 AU B2 631141 EP A1 359190 EP A1 434732 FI A0 911236 FI B 89914 FI C 89914 HU A0 895576 HU A2 55766 HU B 207057 JP T2 3502695 JP B4 5052830 NO A 910879 NO A0 910879 WO A1 9002739	02-04-90 19-11-92 21-03-90 03-07-91 13-03-91 31-08-93 10-12-93 28-05-91 28-06-91 01-03-93 20-06-91 06-08-93 06-03-91 06-03-91 22-03-90
US A 4235892	25-11-80	AR A1 230260 AR A1 230427 AR A1 230428 AT E 2616 AU A1 55078/80 AU B2 532879 CA A1 1137106 DE CO 3062094 DK A 424/80 DK B 159264 DK C 159264 EP A2 14437 EP A3 14437 EP B1 14437 ES A1 488154 ES A5 488154 ES A1 8104203 ES A1 494632 ES A1 494633 ES A5 494632 ES A5 494633 ES A1 8107162 ES A1 8107163 HU B 180555 IE B 49740 IL A0 59288 IL A1 59288 JP A2 55115855 JP B4 59023300 KR B1 8401837 KR B1 8401963 KR B1 8401964 MY A 51/85 NZ A 192774 ZA A 8000478 US A 4511857	01-03-84 30-04-84 30-04-84 15-03-83 10-07-80 20-10-83 07-12-82 31-03-83 06-08-80 24-09-90 18-02-91 20-08-80 29-10-80 23-02-83 16-04-81 13-05-81 01-07-81 16-08-81 16-08-81 16-09-81 16-09-81 16-12-81 16-12-81 28-03-83 11-12-85 30-05-80 29-06-84 06-09-80 01-06-84 22-10-84 26-10-84 26-10-84 31-12-85 24-08-84 28-01-81 19-01-82

EF A1	472790	04-03-92	AU A1	62074/90	05-03-92
			BR A	9004853	31-03-92
			CA AA	2023600	23-02-92
			AU B2	634574	25-02-93
US A	4900847	13-02-90	AU A1	55057/86	09-10-86
			BR A	8601504	09-12-86
			CA A1	1273948	11-09-90
			EP A2	197766	15-10-86
			EP A3	197766	30-09-87
			IL A0	78187	31-07-86
			IL A1	78187	12-05-91
			JP A2	61293978	24-12-86
			JP B4	3054941	21-08-91
			KR B1	9306267	12-07-93